secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-09-12T23:59:59+00:00
Accession:  0001628280-23-032021
Event type: m_and_a
Sentiment:  positive
Materiality: 0.50
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo sells 800 series assets to AUG for $150K upfront, up to $45M in milestones
--------------------------------------------------------------------------------

- Upfront payment of $150,000 plus potential $45M in milestone payments if first FDA approval for non-rare pediatric indication.
- AUG assumes up to $150K of liabilities and all costs from transaction date; closing expected Q4 2023.
- CEO says divestiture refocuses on immunology assets, improves cash flow and reduces resource utilization on non-core.
- Contingent payments of up to 20% of proceeds from any sale of priority review voucher granted by FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023032021/0001628280-23-032021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023032021/avtx-20230911.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-032021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer